Investigating SGLT2 inhibitors for treating hypertrophic cardiomyopathy
SGLT-inhibitors in patients with hypertrophic cardiomyopathy
This study is looking at whether a diabetes medication called SGLT2 inhibitors can help people with non-obstructive hypertrophic cardiomyopathy (HCM) feel better and improve their heart function, giving them more treatment options for their condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10923375 on NIH RePORTER |
What this research studies
This research focuses on patients with hypertrophic cardiomyopathy (HCM), particularly those with non-obstructive HCM, who often face severe symptoms and limited treatment options. The study will explore the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i), originally developed for diabetes, to see if they can improve heart function and reduce symptoms in these patients. By assessing the safety and effectiveness of SGLT2i, the research aims to provide new therapeutic options for managing this challenging condition. Patients will be monitored for changes in heart health and overall well-being throughout the study.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with non-obstructive hypertrophic cardiomyopathy who experience significant symptoms.
Not a fit: Patients with obstructive hypertrophic cardiomyopathy or those without significant symptoms may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could offer a new treatment option that significantly improves the quality of life for patients with non-obstructive hypertrophic cardiomyopathy.
How similar studies have performed: Previous research has shown promising results for SGLT2 inhibitors in improving cardiovascular outcomes, suggesting potential success for this approach in hypertrophic cardiomyopathy.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Day, Sharlene M — University of Pennsylvania
- Study coordinator: Day, Sharlene M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.